Priel E, Showalter S D, Blair D G
Department of Microbiology & Immunology, Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel.
AIDS Res Hum Retroviruses. 1991 Jan;7(1):65-72. doi: 10.1089/aid.1991.7.65.
We examined the effects of topoisomerase inhibitors on human immunodeficiency virus type 1 (HIV-1) infection of H9 cells in cell culture. Infection is blocked or substantially reduced by the topoisomerase I inhibitor camptothecin (CPT), but not by two topoisomerase II inhibitors. Significant reduction (greater than or equal to 90%) in the amount of virus released, as measured by reverse transcriptase, is obtained if the cells are treated for 1 h with 0.01-0.02 microM CPT at the time of virus infection, and expression of viral proteins is also blocked. CPT is also shown to reduce the level of infection when chronically infected cells are cocultivated with uninfected cells. These results with CPT suggest that this compound may represent a new class of drugs with antiretroviral potential.
我们在细胞培养中研究了拓扑异构酶抑制剂对人免疫缺陷病毒1型（HIV-1）感染H9细胞的影响。拓扑异构酶I抑制剂喜树碱（CPT）可阻断或显著减少感染，但两种拓扑异构酶II抑制剂则无此作用。如果在病毒感染时用0.01 - 0.02 microM CPT处理细胞1小时，通过逆转录酶测定，释放的病毒量会显著减少（大于或等于90%），并且病毒蛋白的表达也会被阻断。当长期感染的细胞与未感染的细胞共培养时，CPT也能降低感染水平。CPT的这些结果表明，这种化合物可能代表一类具有抗逆转录病毒潜力的新型药物。
